Spots Global Cancer Trial Database for brain stem glioma
Every month we try and update this database with for brain stem glioma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Intraarterial Infusion Of Erbitux and Bevacizumab For Relapsed/Refractory Intracranial Glioma In Patients Under 22 | NCT01884740 | Glioblastoma Mu... Fibrillary Astr... Glioma of Brain... Anaplastic Astr... Pilomyxoid Astr... Mixed Oligodend... Brain Stem Glio... Diffuse Intrins... | SIACI of Erbitu... | 1 Year - 21 Years | Weill Medical College of Cornell University | |
| Intraarterial Infusion Of Erbitux and Bevacizumab For Relapsed/Refractory Intracranial Glioma In Patients Under 22 | NCT01884740 | Glioblastoma Mu... Fibrillary Astr... Glioma of Brain... Anaplastic Astr... Pilomyxoid Astr... Mixed Oligodend... Brain Stem Glio... Diffuse Intrins... | SIACI of Erbitu... | 1 Year - 21 Years | Weill Medical College of Cornell University | |
| Study of Antineoplaston Therapy + Radiation vs. Radiation Only in Diffuse, Intrinsic, Brainstem Glioma | NCT02887040 | Brain Stem Glio... | Radiation Atengenal Astugenal | 3 Years - 99 Years | Burzynski Research Institute | |
| Phase I Study of Cellular Immunotherapy for Recurrent/Refractory Malignant Glioma Using Intratumoral Infusions of GRm13Z40-2, An Allogeneic CD8+ Cytolitic T-Cell Line Genetically Modified to Express the IL 13-Zetakine and HyTK and to be Resistant to Glucocorticoids, in Combination With Interleukin-2 | NCT01082926 | Anaplastic Astr... Anaplastic Epen... Anaplastic Meni... Anaplastic Olig... Brain Stem Glio... Ependymoblastom... Giant Cell Glio... Glioblastoma Gliosarcoma Grade III Menin... Meningeal Heman... Mixed Glioma Pineal Gland As... Brain Tumor | therapeutic all... aldesleukin laboratory biom... positron emissi... | 18 Years - 70 Years | City of Hope Medical Center | |
| Ritonavir and Lopinavir in Treating Patients With Progressive or Recurrent High-Grade Glioma | NCT01095094 | Brain Tumor Anaplastic Astr... Anaplastic Epen... Anaplastic Olig... Brain Stem Glio... Giant Cell Glio... Glioblastoma Gliosarcoma Mixed Glioma | ritonavir lopinavir | 18 Years - | Case Comprehensive Cancer Center | |
| Amifostine to Protect From Side Effects of PSCT in Treating Patients With Solid Tumors | NCT00003926 | Brain and Centr... Childhood Germ ... Chordoma Kidney Cancer Liver Cancer Neuroblastoma Ovarian Cancer Retinoblastoma Sarcoma | amifostine trih... busulfan filgrastim melphalan thiotepa peripheral bloo... | 1 Year - 45 Years | Masonic Cancer Center, University of Minnesota | |
| Veliparib, Radiation Therapy, and Temozolomide in Treating Younger Patients With Newly Diagnosed Diffuse Pontine Gliomas | NCT01514201 | Anaplastic Astr... Brain Stem Glio... Childhood Mixed... Fibrillary Astr... Giant Cell Glio... Glioblastoma Gliosarcoma Untreated Child... Untreated Child... Untreated Child... Untreated Child... Untreated Child... Untreated Child... | 3-Dimensional C... Intensity-Modul... Laboratory Biom... Pharmacological... Temozolomide Veliparib | - 21 Years | National Cancer Institute (NCI) | |
| Amifostine to Protect From Side Effects of PSCT in Treating Patients With Solid Tumors | NCT00003926 | Brain and Centr... Childhood Germ ... Chordoma Kidney Cancer Liver Cancer Neuroblastoma Ovarian Cancer Retinoblastoma Sarcoma | amifostine trih... busulfan filgrastim melphalan thiotepa peripheral bloo... | 1 Year - 45 Years | Masonic Cancer Center, University of Minnesota | |
| A Study of Aminolevulinic Acid (ALA) to Enhance Visualization and Resection of Malignant Glial Tumors of the Brain | NCT01403311 | Glioma | 5-Aminolevuline... | 18 Years - | Legacy Health System | |
| Immunotherapy for Patients With Brain Stem Glioma and Glioblastoma | NCT00576641 | Brain Stem Glio... Glioblastoma | autologous dend... | - | Cedars-Sinai Medical Center | |
| Study of Antineoplaston Therapy + Radiation vs. Radiation Only in Diffuse, Intrinsic, Brainstem Glioma | NCT02887040 | Brain Stem Glio... | Radiation Atengenal Astugenal | 3 Years - 99 Years | Burzynski Research Institute | |
| Antineoplaston Therapy in Treating Children With Brain Tumors | NCT00003458 | Childhood Brain... | Antineoplaston ... | 6 Months - 18 Years | Burzynski Research Institute | |
| Veliparib, Radiation Therapy, and Temozolomide in Treating Younger Patients With Newly Diagnosed Diffuse Pontine Gliomas | NCT01514201 | Anaplastic Astr... Brain Stem Glio... Childhood Mixed... Fibrillary Astr... Giant Cell Glio... Glioblastoma Gliosarcoma Untreated Child... Untreated Child... Untreated Child... Untreated Child... Untreated Child... Untreated Child... | 3-Dimensional C... Intensity-Modul... Laboratory Biom... Pharmacological... Temozolomide Veliparib | - 21 Years | National Cancer Institute (NCI) | |
| Thalomid and Carboplatin for the Treatment of Pediatric Brain Stem Glioma | NCT00179881 | Brain Stem Neop... Neoplasms, Brai... | Carboplatin Thalomid External Beam R... | 3 Years - 21 Years | Ann & Robert H Lurie Children's Hospital of Chicago | |
| Vorinostat, Temozolomide, or Bevacizumab in Combination With Radiation Therapy Followed by Bevacizumab and Temozolomide in Young Patients With Newly Diagnosed High-Grade Glioma | NCT01236560 | Brain Stem Glio... Cerebral Astroc... Childhood Cereb... Childhood Cereb... Childhood Spina... | Bevacizumab Temozolomide Vorinostat | 3 Years - 21 Years | National Cancer Institute (NCI) | |
| Brain Stem Gliomas Treated With Adoptive Cellular Therapy During Focal Radiotherapy Recovery Alone or With Dose-intensified Temozolomide (Phase I) | NCT03396575 | Diffuse Intrins... Brain Stem Glio... | TTRNA-DC vaccin... TTRNA-xALT Cyclophosphamid... Dose-Intensifie... Td vaccine Autologous Hema... | 3 Years - 30 Years | University of Florida | |
| Photodynamic Therapy (PDT) for Recurrent Pediatric Brain Tumors | NCT01682746 | Brain Tumor, Re... | Photofrin (porf... | 6 Months - 18 Years | Medical College of Wisconsin | |
| Photodynamic Therapy (PDT) for Recurrent Pediatric Brain Tumors | NCT01682746 | Brain Tumor, Re... | Photofrin (porf... | 6 Months - 18 Years | Medical College of Wisconsin | |
| Study of Antineoplaston Therapy + Radiation vs. Radiation Only in Diffuse, Intrinsic, Brainstem Glioma | NCT02887040 | Brain Stem Glio... | Radiation Atengenal Astugenal | 3 Years - 99 Years | Burzynski Research Institute | |
| Photodynamic Therapy (PDT) for Recurrent Pediatric Brain Tumors | NCT01682746 | Brain Tumor, Re... | Photofrin (porf... | 6 Months - 18 Years | Medical College of Wisconsin | |
| Antineoplaston Therapy in Treating Children With Brain Tumors | NCT00003458 | Childhood Brain... | Antineoplaston ... | 6 Months - 18 Years | Burzynski Research Institute | |
| Veliparib, Radiation Therapy, and Temozolomide in Treating Younger Patients With Newly Diagnosed Diffuse Pontine Gliomas | NCT01514201 | Anaplastic Astr... Brain Stem Glio... Childhood Mixed... Fibrillary Astr... Giant Cell Glio... Glioblastoma Gliosarcoma Untreated Child... Untreated Child... Untreated Child... Untreated Child... Untreated Child... Untreated Child... | 3-Dimensional C... Intensity-Modul... Laboratory Biom... Pharmacological... Temozolomide Veliparib | - 21 Years | National Cancer Institute (NCI) |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
